Active Ingredient History
The Vi capsular polysaccharide vaccine is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid. The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Typhoid-Paratyphoid Vaccines (approved 1994)
Acute Coronary Syndrome (Phase 1)
Bacterial Infections (Phase 3)
Deficiency Diseases (Phase 4)
Diarrhea (Phase 1/Phase 2)
Encephalitis, Japanese (Phase 3)
Healthy Volunteers (Phase 4)
Hepatitis A (Phase 4)
Inflammation (Phase 1)
Influenza, Human (Phase 4)
Malaria (Phase 2)
Meningitis, Meningococcal (Phase 3)
Meningococcal Infections (Phase 3)
Myocardial Infarction (Phase 1)
Paratyphoid Fever (Phase 4)
Rabies (Phase 3)
Reperfusion Injury (Phase 1)
Salmonella Infections (Phase 3)
Stress Disorders, Post-Traumatic (Early Phase 1)
Typhoid Fever (Phase 4)
Yellow Fever (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue